

#### **ASX ANNOUNCEMENT**

## **Addendum to Notice of Annual General Meeting**

MELBOURNE, Australia (13 October 2025) – Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") wishes to advise that information supplementary to the Company's original Notice of Annual General Meeting ("Notice") has been released and is contained in this Addendum to the Company's Notice of Annual General Meeting ("Addendum"), as outlined under Schedule 1 of this announcement. Per Section 12 of ASX Guidance Note 35, shareholders are being provided with at least 10 days to consider the supplementary information contained in this Addendum.

This Addendum is supplementary to the original Notice announced to the market on 19 September 2025 and should be read alongside it. Except for the amendments outlined under the Addendum, all Resolutions and the Explanatory Statement in the original Notice remain unchanged.

The Company confirms that there are no changes to the Proxy Form previously provided to shareholders. Proxies already cast in relation to the Annual General Meeting to be held on Friday, 24 October 2025 at 9.30am (AEDT) remain valid unless withdrawn prior to the Meeting. Shareholders can recast their proxy votes by voting online at <a href="https://www.investorvote.com.au">www.investorvote.com.au</a> using their secure access information or by requesting a copy of their proxy form through the share registry, Computershare, by calling on 1300 850 505 (within Australia) or +61 3 9415 400 (outside Australia).

Unless the context otherwise requires, capitalised terms used in this Addendum have the meanings given to them in the Notice.

### Reason for the Addendum

The Addendum is in relation to Resolutions 3 and 4 of the Notice pertaining to the proposed issue of performance rights to Mr Douglas Ward, Managing Director and Chief Executive Officer of the Company, and is in response to queries received from Shareholders on the timing and vesting conditions of these performance rights. Additional details have been included under each resolution and the corresponding Explanatory statement, as outlined under Schedule 1.

#### Information

This Addendum should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their suitably qualified professional advisors prior to voting.

This Addendum does not affect the validity of the proxy form attached to the original Notice of Meeting announced to the market on 19 September 2025, nor will it impact any proxy votes already submitted for the remaining resolutions to be considered for shareholder approval.

Shareholders should contact the Company Secretary on (03) 9087 1598 if they have any queries in respect to the matters set out in this Addendum.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

### **About Lumos Diagnostics**

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

### **Forward-Looking Statements**

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

#### **Media Contact:**

Haley Chartres – Australia H^CK Director haley@hck.digital +61 (0) 423 139 163

#### **Investor Contact:**

George Kopsiaftis
IR Department
ir@lumosdiagnostics.com
+61 409 392 687

### **Company Registered Office:**

Lumos Diagnostics Holdings Ltd Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 Australia +61 3 9087 1598

#### SCHEDULE 1 – ADDENDUM TO THE NOTICE OF ANNUAL GENERAL MEETING

Amendments to Resolution 3 outlined on page 2 of the Notice

Resolution 3: Approval to issue 10,000,000 FY25 LTI related performance rights to Mr Douglas Ward

To consider and, if thought fit, pass the following resolution as an ordinary resolution:

"That the grant of 10,000,000 FY25 Long Term Incentive Plan related performance rights (being a right to acquire up to 10,000,000 fully paid ordinary shares in the Company, subject to satisfaction of relevant vesting conditions), and the issue of any fully paid ordinary shares in the Company pursuant to the exercise or conversion of such performance rights, to Mr Douglas Ward, Managing Director and Chief Executive Officer of the Company, under the Company's Long Term Incentive Plan and on the terms described in the Explanatory Statement, be approved under and for the purpose of Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes."

Amendments to Resolution 4 outlined on page 3 of the Notice

Resolution 4: Approval to issue 12,000,000 FY26 LTI related performance rights to Mr Douglas Ward

To consider and, if thought fit, pass the following resolution as an ordinary resolution:

"That the grant of 12,000,000 FY26 Long Term Incentive Plan related performance rights (being a right to acquire up to 12,000,000 fully paid ordinary shares in the Company, subject to satisfaction of relevant vesting conditions), and the issue of any fully paid ordinary shares in the Company pursuant to the exercise or conversion of such performance rights, to Mr Douglas Ward, Managing Director and Chief Executive Officer of the Company, under the Company's Long Term Incentive Plan and on the terms described in the Explanatory Statement, be approved under and for the purpose of Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes."

Amendments to the Explanatory Statement regarding Resolutions 3 and 4 of the Notice outlined from page 10 to 16 of the Notice

Resolution 3: Approval to issue 10,000,000 FY25 LTI related performance rights to Mr Douglas Ward (or his nominee)

Resolution 4: Approval to issue 12,000,000 FY26 LTI related performance rights to Mr Douglas Ward (or his nominee)

#### **Background**

The Company proposes, subject to Shareholder approval, to grant and issue to Mr Ward, Managing Director and Chief Executive Officer:

 a) Under Resolution 3 - 10,000,000 FY25 LTI related performance rights which, if they vest, will result in the issue of up to 10,000,000 fully paid ordinary shares in the Company pursuant to the Company's Long Term Incentive Plan ("LTIP"); b) Under Resolution 4 - 12,000,000 FY26 LTI related performance rights which, if they vest, will result in the issue of up to 12,000,000 fully paid ordinary shares in the Company pursuant to the Company's LTIP.

For the avoidance of doubt, the performance rights are not a 'bonus' or 'bonus shares' — performance rights cannot be traded or sold or exchanged for any monetary value. Performance rights only vest and result in the issue of fully paid ordinary shares in the Company if, and to the extent that, the vesting conditions are satisfied and will be issued and vest in accordance with the terms and conditions of the LTIP Rules. Otherwise, the performance rights will lapse, and no Shares will be issued in relation to them.

On 8 May 2025, the Company formalised and issued FY25 LTI related performance rights to employees under the Company's Long Term Incentive Plan, other than Mr Ward. The proposed issue of performance rights to Mr Ward contemplated by Resolution 3 is on the same terms as those issued to the other employees.

The Company is proposing to formalise the issue of 10,000,000 FY25 LTI related performance rights to Mr Ward under Resolution 3 where the aim of this FY25 related issue was to increase Mr Ward's interests in the Company to approximately 5% of the total number of securities on issue in the Company at the time of the employee related rights issue (8 May 2025).

The Company is proposing a further issue of 12,000,000 FY26 LTI related performance rights to Mr Ward under Resolution 4 to maintain his interests in the Company to approximately 5% of the total number of securities on issue in the Company, aligning his interests with that of the Shareholders of the Company.

Due to the timing of both the FY25 and FY26 Lumos remuneration cycles relative to the annual AGMs, the shareholders are being asked to consider two separate tranches of LTI performance rights for Mr Ward. The Board believes that it is appropriate to use performance rights to incentivise Mr Ward as this remunerates him appropriately given the circumstances of the Company. In establishing appropriate and specific vesting conditions for each tranche of the performance rights, the Board believes these rights are tailored to support the needs of the business at the time and therefore, align with Shareholder interests. The Board believes that the ownership of performance rights will be to the benefit of all Shareholders as this will motivate Mr Ward to remain in the Company's employ to carry on the role of implementing and executing the Company's strategies and overseeing operations. In particular, the Board considers that the value attributed to the performance rights (as described below) represents reasonable remuneration for Mr Ward as if the Company and Mr Ward were dealing at arm's length.

Resolution 3 seeks Shareholder approval to grant 10,000,000 FY25 LTI related performance rights, and to issue 10,000,000 Shares in the Company, subject to satisfaction of relevant vesting conditions, to Mr Doug Ward, under the Company's LTIP and the terms described in the Explanatory Statement.

Resolution 4 seeks Shareholder approval to grant 12,000,000 FY26 LTI related performance rights, and to issue 12,000,000 Shares in the Company subject to satisfaction of relevant vesting conditions, to Mr Doug Ward, under the Company's LTIP and the terms described in the Explanatory Statement.

# Amendments to the Terms of performance rights under Resolution 3

Terms	
Туре	Performance Rights
Number	10,000,000
Consideration	Nil consideration
Vesting Conditions	Subject to Shareholder approval, the relevant period commencing from 8 May 2025 ("Grant Date") and ending as follows:  Tranche 1 (50%, being 5,000,000): 12 months from the Grant Date ("Vesting Date 1")
	<ul> <li>Tranche 2 (50%, being 5,000,000): 24 months from the Grant Date ("Vesting Date 2")</li> </ul>
	Vesting of the performance rights are also subject to service condition of continued employment being satisfied at time of Vesting Date(s).
	The Performance Rights automatically convert to shares upon vesting.
Restrictions on Dealing	The performance rights are not transferrable.
	Once vesting conditions have been achieved, and the performance rights have been converted into Shares, Mr Ward will be able to deal with the Shares issued to him under this Resolution, subject to the requirements of the Company's Securities Trading Policy.
Other terms	The performance rights automatically convert into Shares upon vesting.
	The Performance Rights will expire if Mr Ward ceases employment or other engagement with the Company during the vesting period.

# Amendments to the Terms of performance rights under Resolution 4

Terms	
Туре	Performance Rights
Number	12,000,000
Consideration	Nil consideration
Vesting Conditions	<ul> <li>From the date of Shareholder approval ("Grant Date") and ending as follows:</li> <li>Tranche 1 (50%, being 6,000,000): At the grant of CLIA waiver for FebriDx by the US FDA ("Vesting Date 1")</li> <li>Tranche 2 (50%, being 6,000,000): 24 months from the Grant Date ("Vesting Date 2")</li> <li>Vesting of the performance rights are also subject to service condition of continued employment being satisfied at time of Vesting Date(s).</li> <li>The Performance Rights automatically convert to shares upon vesting.</li> </ul>
Restrictions on Dealing	The performance rights are not transferrable.  Once vesting conditions have been achieved, and the performance rights have been converted into Shares, Mr Ward will be able to deal with the Shares issued to him under this Resolution, subject to the requirements of the Company's Securities Trading Policy.
Other terms	The performance rights automatically convert into Shares upon vesting.  The Performance Rights will expire if Mr Ward ceases employment or other engagement with the Company during the vesting period.